Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA)

PHASE2CompletedINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

March 18, 2019

Primary Completion Date

August 4, 2023

Study Completion Date

August 4, 2023

Conditions
Autism Spectrum Disorder
Interventions
DRUG

Arbaclofen

Administered orally as disintegrating tabs, round, white and beveled edges, at the following strengths: 5mg, 10mg, 15mg and 20mg

OTHER

Placebo

Administered orally as disintegrating tabs, round, white and beveled edges

Trial Locations (4)

L8S 4K1

McMaster University, Offord Centre for Child Studies, Hamilton

K7M 8A6

Queen's Universtiy, Kingston

N6A 5W9

University of Western Ontario, Lawson Health Research Institute, London

M4G 1R8

Holland Bloorview Kids Rehabilitation Hospital, Toronto

All Listed Sponsors
collaborator

McMaster University

OTHER

collaborator

Western University, Canada

OTHER

collaborator

Queen's University

OTHER

collaborator

Unity Health Toronto

OTHER

collaborator

University of Toronto

OTHER

lead

Holland Bloorview Kids Rehabilitation Hospital

OTHER

NCT03887676 - Arbaclofen vs. Placebo in the Treatment of Children and Adolescents With ASD (ARBA) | Biotech Hunter | Biotech Hunter